Gilead Sciences Beats Sales and Earnings; Guidance Disappoints

GILD Shares of biotechnology provider Gilead Sciences, Inc. (NASDAQ: GILD – $73.13) retreated about 3% after the company put out disappointing 2017 sales guidance. Fourth-quarter adjusted earnings per share was $2.70, above the Street consensus of $2.61, but lower than last year’s $3.32. Although revenue fell to $7.3 billion from $8.5 billion, it was also above analysts’ consensus of $7.1 billion. The company now expects 2017 sales of $22.5 billion to $24.5 billion, less than what Wall Street was estimating at closer to $27.9 billion and below 2016’s $30 billion. Flagging sales for the company’s hepatitis C franchise continues to weigh on the shares. Quarterly sales of hepatitis C drugs Sovaldi, Harvoni and recently Epclusa totaled $3.2 billion, compared with $4.9 billion a year earlier. 

       Gilead’s HIV franchise remains incomparable and is still the flagship earnings driver. The dividend is decent (2.6% yield) and will likely be hiked. Lastly, a large acquisition cannot be far off with the company’s $12.3 billion cash hoard. The shares are, in my opinion, undervalued and the company’s drug pipeline has improved. I am going to maintain my position in the aggressive account for long-term recovery.

gild

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: